Civica Rx says it isn't afraid of competition

Civica Rx CEO Martin VanTrieste isn't afraid of competition, he says. In fact, he welcomes organizations that want to disrupt the system and reduce drug shortages affecting patient care, according to S&P Global.

Some companies are already adopting their own disruptive models, including Premier Inc., which recently launched Provide Gx, Mr. Van Trieste told S&P Global. 

He also cited a "remarkably similar" proposal by Sen. Elizabeth Warren, D-Mass., that would give the U.S. government power to make generic medications. 

Civica Rx was formed in September 2018 by a coalition of hospitals that sought to create a company to reduce the generic drug shortage in the U.S.

The nonprofit company expects to have its first product, the antibiotic vancomycin, available for hospitals by the end of this month.

"In my entire career, I've never seen anything take shape and have that much momentum and deliver so many results in such a fast period of time," Mr. VanTrieste told S&P Global.

Civica Rx expects to bring 16 products to market this year, according to the report.  Mr. VanTrieste said there are more than 200 drugs on the FDA's shortage list.

More articles on pharmacy:
FDA approves AbbVie's $59K rheumatoid arthritis drug
Teva launches generic version of EpiPen for kids
American Regent boosted price of essential hospital product by 1,300%

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months